Key result
New class III antiarrhythmic drugs show efficacy against re-entrant arrhythmias but carry a substantial proarrhythmic risk, particularly torsade de pointes, necessitating careful clinical evaluation.
Why the study?
Do new class III antiarrhythmic drugs suppress arrhythmias and prevent arrhythmic sudden death?
Do new class III antiarrhythmic drugs suppress arrhythmias and prevent arrhythmic sudden death?
Answers are grounded in this paper and cite their sources.
New class III antiarrhythmic drugs show promise in treating supraventricular and ventricular arrhythmias but require careful clinical evaluation due to the risk of torsade de pointes.
Several new antiarrhythmic compounds with pure class III activity are currently under development and seem to possess considerable antiarrhythmic potential. The primary electrophysiological action of class III agents is selective prolongation of repolarization without conduction slowing. This effect is usually mediated by block of one or more potassium currents which results in prolongation of the action-potential duration and refractoriness in both atrial and ventricular myocardium. The magnitude of increases in effective refractory period decreases as the heart rate is increased, i.e. these drugs display 'reverse use-dependence'. Initial animal and clinical studies have shown that class III agents are effective against re-entrant supraventricular and ventricular arrhythmias without having any important negative inotropic effect in the compromised ventricle. Animal studies have also suggested that these drugs may be useful in suppressing postinfarction arrhythmias and preventing arrhythmic sudden death. However, concerns have been raised by reports of substantial proarrhythmic tendency associated with these drugs, mainly in the form of torsade de pointes. Careful clinical evaluation is required to establish the clinical benefits of these potentially promising new compounds.
No takes yet. Share an insight, caveat, or question.
Katritsis et al. (1993) conducted a review in Arrhythmias. New class III antiarrhythmic drugs was evaluated. New class III antiarrhythmic drugs show efficacy against re-entrant arrhythmias but carry a substantial proarrhythmic risk, particularly torsade de pointes, necessitating careful clinical evaluation.
Synapse has enriched 10 related papers. Consider them for comparative context: